NuCana plc (NCNA) - Quarterly EPS earnings growth

Official company branding of NuCana PLC (NCNA)

Clinical phase delays are hindering sales expansion, which correlates with the volatility seen in quarterly earnings per share dynamics for NuCana plc (NCNA). Meanwhile, -248.30 shapes the current metric. Growth potential is based on the ProTide technology that destroys tumor DNA, while operational flexibility is ensured by fully outsourcing production and trials to external partners.

NuCana (NCNA) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for NuCana plc

- market value and analyst target forecast:
Fundamental company analysis:NuCana PLC, NCNA
Manufactured product of NuCana plc

To assess the credit quality of NuCana plc (NCNA), the analyst examines the quarterly EPS growth vector, which measures net income per share dynamics relative to revenue and margins to exclude fictitious returns. The stability of this metric is supported by a clinical trial outsourcing model via CRO vendors, which minimizes capital expenditures and confirms the reality of financial expansion without excessive operating costs.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Corbus Pharma CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma, Ltd.)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kazia (KZIA)|Year-over-year earnings per share growth for the last twelve months silexion.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc